REVOLUTION MEDICINES INC (RVMD) Fundamental Analysis & Valuation
NASDAQ:RVMD • US76155X1000
Current stock price
96.22 USD
-0.53 (-0.55%)
At close:
96.06 USD
-0.16 (-0.17%)
After Hours:
This RVMD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. RVMD Profitability Analysis
1.1 Basic Checks
- RVMD had negative earnings in the past year.
- In the past year RVMD has reported a negative cash flow from operations.
- RVMD had negative earnings in each of the past 5 years.
- In the past 5 years RVMD always reported negative operating cash flow.
1.2 Ratios
- The Return On Assets of RVMD (-48.05%) is comparable to the rest of the industry.
- RVMD has a Return On Equity (-69.35%) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -48.05% | ||
| ROE | -69.35% | ||
| ROIC | N/A |
ROA(3y)-30.89%
ROA(5y)-29.73%
ROE(3y)-39.91%
ROE(5y)-37.42%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for RVMD so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. RVMD Health Analysis
2.1 Basic Checks
- Compared to 1 year ago, RVMD has more shares outstanding
- RVMD has more shares outstanding than it did 5 years ago.
- RVMD has a worse debt/assets ratio than last year.
2.2 Solvency
- RVMD has an Altman-Z score of 13.45. This indicates that RVMD is financially healthy and has little risk of bankruptcy at the moment.
- The Altman-Z score of RVMD (13.45) is better than 84.33% of its industry peers.
- A Debt/Equity ratio of 0.16 indicates that RVMD is not too dependend on debt financing.
- RVMD has a worse Debt to Equity ratio (0.16) than 65.57% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.16 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 13.45 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- A Current Ratio of 7.14 indicates that RVMD has no problem at all paying its short term obligations.
- With a decent Current ratio value of 7.14, RVMD is doing good in the industry, outperforming 67.12% of the companies in the same industry.
- RVMD has a Quick Ratio of 7.14. This indicates that RVMD is financially healthy and has no problem in meeting its short term obligations.
- RVMD's Quick ratio of 7.14 is fine compared to the rest of the industry. RVMD outperforms 67.50% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.14 | ||
| Quick Ratio | 7.14 |
3. RVMD Growth Analysis
3.1 Past
- The earnings per share for RVMD have decreased strongly by -65.55% in the last year.
EPS 1Y (TTM)-65.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-66.07%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- Based on estimates for the next years, RVMD will show a very strong growth in Earnings Per Share. The EPS will grow by 24.93% on average per year.
- RVMD is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 284.00% yearly.
EPS Next Y-26.4%
EPS Next 2Y-4.68%
EPS Next 3Y4.8%
EPS Next 5Y24.93%
Revenue Next Year1132.72%
Revenue Next 2Y694.05%
Revenue Next 3Y463.33%
Revenue Next 5Y284%
3.3 Evolution
4. RVMD Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for RVMD. In the last year negative earnings were reported.
- Also next year RVMD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-4.68%
EPS Next 3Y4.8%
5. RVMD Dividend Analysis
5.1 Amount
- RVMD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
RVMD Fundamentals: All Metrics, Ratios and Statistics
96.22
-0.53 (-0.55%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-25 2026-02-25/amc
Earnings (Next)05-05 2026-05-05/amc
Inst Owners100.47%
Inst Owner Change0%
Ins Owners1.82%
Ins Owner Change0.12%
Market Cap19.07B
Revenue(TTM)N/A
Net Income(TTM)-1.13B
Analysts87.41
Price Target136.84 (42.22%)
Short Float %7.58%
Short Ratio5.75
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-13.3%
Min EPS beat(2)-15.36%
Max EPS beat(2)-11.24%
EPS beat(4)0
Avg EPS beat(4)-10.23%
Min EPS beat(4)-15.36%
Max EPS beat(4)-1.54%
EPS beat(8)1
Avg EPS beat(8)-6.23%
EPS beat(12)3
Avg EPS beat(12)-5.8%
EPS beat(16)6
Avg EPS beat(16)-2.46%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)10.02%
PT rev (3m)62.32%
EPS NQ rev (1m)-3.03%
EPS NQ rev (3m)-9.64%
EPS NY rev (1m)0%
EPS NY rev (3m)-14.25%
Revenue NQ rev (1m)-13.34%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)15.59%
Revenue NY rev (3m)61.46%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 11.69 | ||
| P/tB | 12.22 | ||
| EV/EBITDA | N/A |
EPS(TTM)-5.91
EYN/A
EPS(NY)-7.47
Fwd EYN/A
FCF(TTM)-4.61
FCFYN/A
OCF(TTM)-4.53
OCFYN/A
SpS0
BVpS8.23
TBVpS7.88
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -48.05% | ||
| ROE | -69.35% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-30.89%
ROA(5y)-29.73%
ROE(3y)-39.91%
ROE(5y)-37.42%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.16 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 184.86% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 7.14 | ||
| Quick Ratio | 7.14 | ||
| Altman-Z | 13.45 |
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)148.83%
Cap/Depr(5y)163.7%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-65.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-66.07%
EPS Next Y-26.4%
EPS Next 2Y-4.68%
EPS Next 3Y4.8%
EPS Next 5Y24.93%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year1132.72%
Revenue Next 2Y694.05%
Revenue Next 3Y463.33%
Revenue Next 5Y284%
EBIT growth 1Y-71.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-40.29%
EBIT Next 3Y2.44%
EBIT Next 5Y23.57%
FCF growth 1Y-60.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-61.05%
OCF growth 3YN/A
OCF growth 5YN/A
REVOLUTION MEDICINES INC / RVMD Fundamental Analysis FAQ
What is the ChartMill fundamental rating of REVOLUTION MEDICINES INC (RVMD) stock?
ChartMill assigns a fundamental rating of 2 / 10 to RVMD.
What is the valuation status for RVMD stock?
ChartMill assigns a valuation rating of 0 / 10 to REVOLUTION MEDICINES INC (RVMD). This can be considered as Overvalued.
Can you provide the profitability details for REVOLUTION MEDICINES INC?
REVOLUTION MEDICINES INC (RVMD) has a profitability rating of 1 / 10.
What is the expected EPS growth for REVOLUTION MEDICINES INC (RVMD) stock?
The Earnings per Share (EPS) of REVOLUTION MEDICINES INC (RVMD) is expected to decline by -26.4% in the next year.